TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39297720

Group type: EXPERIMENTAL
Intervention: Primary CPSP model
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Secondary threshold-based CPSP model
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Preoperative and postoperative threshold-based models
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Threshold-based models
Number of subjects: 960
Study: 39297745

Group type: EXPERIMENTAL
Intervention: Calcineurin inhibitors (Group A)
Number of subjects: 508

Group type: COMPARATOR
Intervention: Mammalian target of rapamycin inhibitors (sirolimus - Group B)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: R3-AFP score
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Calibration of the R3-AFP model
Number of subjects: 508
Study: 39297834

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 39297839

Group type: EXPERIMENTAL
Intervention: 14-day continuous electrocardiogram patch monitor
Number of subjects: 5684
Study: 39297854

Group type: EXPERIMENTAL
Intervention: Thrombus aspiration (TA)
Number of subjects: 812
Study: 39297855

Group type: EXPERIMENTAL
Intervention: GORE CARDIOFORM ASD Occluder (GCA)
Number of subjects: 569
Study: 39297940

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313
Study: 39297964

Group type: EXPERIMENTAL
Intervention: Monofilament threshold testing
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: SPPB - Balance Subscale
Number of subjects: 142
Study: 39298144

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) of 48 Gy in 4 fractions (peripheral NSCLC) or 60 Gy in 8 fractions (central NSCLC)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Hypofractionated conventional radiotherapy (CRT) of 60 Gy in 15 fractions
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: SBRT
Number of subjects: 233

Group type: COMPARATOR
Intervention: SBRT and CRT
Number of subjects: 233
Study: 39298147

Group type: EXPERIMENTAL
Intervention: Rogaratinib 600 mg or 800 mg twice daily plus atezolizumab 1200 mg every 21 days
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Rogaratinib plus atezolizumab
Number of subjects: 73
Study: 39298170

Group type: EXPERIMENTAL
Intervention: WELL-B intervention (5 hours over 8 days)
Number of subjects: 643

Group type: COMPARATOR
Intervention: Control group (received WELL-B after the end of the RCT)
Number of subjects: 643
Study: 39298171

Group type: EXPERIMENTAL
Intervention: Static testing strategy (tests offered once every 2 weeks)
Number of subjects: 2389

Group type: EXPERIMENTAL
Intervention: Dynamic testing strategy (tests offered once a week, once every 2 weeks, or once a month depending on county COVID-19 infection prevalence)
Number of subjects: 2389

Group type: COMPARATOR
Intervention: Older patients (per 5-year age increment)
Number of subjects: 2389

Group type: COMPARATOR
Intervention: Patients with diabetes vs without diabetes
Number of subjects: 2389

Group type: COMPARATOR
Intervention: Women compared with men
Number of subjects: 2389

Group type: COMPARATOR
Intervention: Hispanic patients compared with White patients
Number of subjects: 2389

Group type: COMPARATOR
Intervention: Patients living in Republican-leaning zip codes compared to Democratic-leaning zip codes
Number of subjects: 2389
Study: 39298511

Group type: EXPERIMENTAL
Intervention: Carbon monoxide poisoning
Number of subjects: 48600
Study: 39298716

Group type: EXPERIMENTAL
Intervention: Palbociclib (75 mg/m² orally once daily for 21 days of 28-day cycles)
Number of subjects: 23
Study: 39298718

Group type: EXPERIMENTAL
Intervention: Pembrolizumab + Radiation Therapy (RT)
Number of subjects: 66
Study: 39298738

Group type: EXPERIMENTAL
Intervention: Targeted pretransplant regimen involving the anti-CD45 radioconjugate
Number of subjects: 153

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 153
Study: 39298750

Group type: EXPERIMENTAL
Intervention: Gamified web app (DuCATA_GAM-CaT)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Predictive analysis techniques
Number of subjects: 74
Study: 39298763

Group type: EXPERIMENTAL
Intervention: Vira+Coaching
Number of subjects: 73

Group type: COMPARATOR
Intervention: Vira Self-Care
Number of subjects: 73
Study: 39298831

Group type: EXPERIMENTAL
Intervention: Good LIPI
Number of subjects: 153

Group type: COMPARATOR
Intervention: Intermediate/Poor LIPI
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: Persistently inter/poor LIPI
Number of subjects: 153

Group type: COMPARATOR
Intervention: Persistently good LIPI
Number of subjects: 153
Study: 39299058

Group type: EXPERIMENTAL
Intervention: Artificial Intelligence (AI) group (n=94)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control group (n=94)
Number of subjects: 188
Study: 39299389

Group type: EXPERIMENTAL
Intervention: Airway Pressure Release Ventilation (APRV)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low Tidal Volume (LTV) Ventilation
Number of subjects: 40
Study: 39299540

Group type: EXPERIMENTAL
Intervention: Congestion index alerts
Number of subjects: 329

Group type: COMPARATOR
Intervention: Standard weight rule
Number of subjects: 329
Study: 39299543

Group type: EXPERIMENTAL
Intervention: Fasting group (24-h fast one day per week for 12 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fasting/weight maintenance group (24-h fast one day per week for 12 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fasting group
Number of subjects: 0
Study: 39299544

Group type: EXPERIMENTAL
Intervention: Trauma Resilience and Recovery Program (TRRP)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 350
Study: 39299545

Group type: EXPERIMENTAL
Intervention: Time Restricted Eating (TRE)
Number of subjects: 247

Group type: COMPARATOR
Intervention: Current Practice (CP)
Number of subjects: 247
Study: 39299559

Group type: EXPERIMENTAL
Intervention: Simnotrelvir/ritonavir co-administered with itraconazole (strong CYP3A and P-gp inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simnotrelvir/ritonavir co-administered with midazolam (CYP3A substrate)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simnotrelvir/ritonavir alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simnotrelvir/ritonavir co-administered with rifampicin (strong CYP3A and P-gp inducer)
Number of subjects: 0
Study: 39299591

Group type: EXPERIMENTAL
Intervention: Sanvello (digital mental health intervention) for 8 weeks
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Sanvello (digital mental health intervention)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 280
Study: 39299726

Group type: EXPERIMENTAL
Intervention: Microbial signatures associated with SLE and IBD
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Predictive biomarkers from species profiles and functional genes
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Protein-protein interaction analyses
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Experimental validation of interactions
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Insights into therapeutic implications
Number of subjects: 6
Study: 39299734

Group type: EXPERIMENTAL
Intervention: Oral anticoagulation (OAC) started according to the '1-3-6-12 days rule' in 255 patients (39.2%).
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: Non-vitamin K-dependent OAC started in 521 patients.
Number of subjects: 708

Group type: EXPERIMENTAL
Intervention: OAC restarted within 3 months of stroke/TIA.
Number of subjects: 708
Study: 39300008

Group type: EXPERIMENTAL
Intervention: Oxytocin maintenance infusion at 4.5 IU·hr
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1-IU oxytocin bolus followed by maintenance infusion
Number of subjects: 40
Study: 39300055

Group type: EXPERIMENTAL
Intervention: Calf Circumference (CC)
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: SARC-F
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: SARC-CalF
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: BMI-adjusted CC
Number of subjects: 228
Study: 39300077

Group type: EXPERIMENTAL
Intervention: Liposomal irinotecan HR070803 combined with 5-fluorouracil (5-FU) and leucovorin (LV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 0
Study: 39300222

Group type: COMPARATOR
Intervention: Ibrutinib 140 mg/day
Number of subjects: 1162

Group type: EXPERIMENTAL
Intervention: Ibrutinib 280 mg/day
Number of subjects: 1162

Group type: EXPERIMENTAL
Intervention: Ibrutinib 420 mg/day
Number of subjects: 1162

Group type: EXPERIMENTAL
Intervention: Ibrutinib 560 mg/day
Number of subjects: 1162

Group type: EXPERIMENTAL
Intervention: Ibrutinib >560 mg/day
Number of subjects: 1162

Group type: EXPERIMENTAL
Intervention: Overall analysis of IRAF reporting
Number of subjects: 1162
Study: 39300290

Group type: EXPERIMENTAL
Intervention: Echocardiography screening
Number of subjects: 1201

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1201
Study: 39300320

Group type: EXPERIMENTAL
Intervention: Telaglenastat (CB-839) combined with azacytidine (AZA)
Number of subjects: 30
Study: 39300328

Group type: EXPERIMENTAL
Intervention: Illness perception measured using the Brief Illness Perception Questionnaire (BIPQ)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Depressive symptoms measured using the Patient Health Questionnaire-9 (PHQ-9)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Anxiety measured using the Generalized Anxiety Disorder-7 (GAD-7)
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Coping strategies measured using the Brief-COPE Scale
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: AF symptoms measured using the Atrial Fibrillation Severity Scale (AFSS)
Number of subjects: 178
Study: 39300363

Group type: EXPERIMENTAL
Intervention: Cognitive remediation (NEAR) combined with standard psychiatric rehabilitation, conducted three times a week for 12 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard psychiatric rehabilitation only.
Number of subjects: 0
Study: 39300364

Group type: EXPERIMENTAL
Intervention: Extended postnatal prophylaxis (PNP) with lamivudine until end of follow-up or end of breastfeeding; all 18 infants eligible for PNP initiated on lamivudine.
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Point-of-care early infant diagnosis (EID) performed at EPI-2 (8 weeks).
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Antiretrovirals prescribed to all mothers.
Number of subjects: 102
Study: 39300376

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) combined with Simvastatin (SIM) plus gemcitabine/nab-paclitaxel-based regimens (AG or PAXG)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Chemotherapy alone (standard arm)
Number of subjects: 240
Study: 39300414

Group type: EXPERIMENTAL
Intervention: Education and Resources (E&R)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Multisectoral Community Collaborative Care (MCC)
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: MCC + Technology
Number of subjects: 700

Group type: COMPARATOR
Intervention: E&R
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: MCC
Number of subjects: 700
Study: 39300419

Group type: EXPERIMENTAL
Intervention: Sleep intervention
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 75
Study: 39300443

Group type: EXPERIMENTAL
Intervention: Imagery-competing task intervention
Number of subjects: 144

Group type: COMPARATOR
Intervention: Attention-based control task
Number of subjects: 144
Study: 39300447

Group type: EXPERIMENTAL
Intervention: Ibrutinib (560 mg daily D3-14 and D17-28) in combination with R-MPV
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Lenalidomide (15 mg daily D1-21) in combination with R-MPV
Number of subjects: 26

Group type: COMPARATOR
Intervention: Both arms (Ibrutinib and Lenalidomide)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Lenalidomide
Number of subjects: 26

Group type: COMPARATOR
Intervention: Both arms
Number of subjects: 26
Study: 39300465

Group type: EXPERIMENTAL
Intervention: Water, Sanitation and Hygiene (WASH) intervention
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Standard national treatment of uncomplicated SAM
Number of subjects: 2000
Study: 39300483

Group type: EXPERIMENTAL
Intervention: Enteral cholecalciferol (10,000 IU/kg, max 400,000 IU)
Number of subjects: 766

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 766
Study: 39300513

Group type: EXPERIMENTAL
Intervention: IV secukinumab (6 mg/kg at baseline followed by 3 mg/kg every four weeks)
Number of subjects: 526

Group type: COMPARATOR
Intervention: IV placebo
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: IV secukinumab (3 mg/kg every four weeks after switching from placebo)
Number of subjects: 526

Group type: EXPERIMENTAL
Intervention: IV secukinumab
Number of subjects: 526
Study: 39300529

Group type: EXPERIMENTAL
Intervention: rTMS-active treatment for 10 consecutive days (n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: rTMS-sham treatment for 10 consecutive days (n=10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: rTMS-active treatment
Number of subjects: 20
Study: 39300555

Group type: EXPERIMENTAL
Intervention: Implementation strategies (educational meetings, outcome measure champions, equipment provision, training materials, documentation system adaptation)
Number of subjects: 200
Study: 39300596

Group type: EXPERIMENTAL
Intervention: IV secukinumab (6 mg/kg at baseline followed by 3 mg/kg every four weeks)
Number of subjects: 381

Group type: COMPARATOR
Intervention: Placebo (switched to IV secukinumab at week 16)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: IV secukinumab (continued treatment through week 52)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: IV secukinumab
Number of subjects: 381

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 381
Study: 39300794

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks
Number of subjects: 724

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 724
Study: 39300870

Group type: EXPERIMENTAL
Intervention: Strengthening coping strategies and treatment expectations
Number of subjects: 0
Study: 39300911

Group type: EXPERIMENTAL
Intervention: Heart Rate (HR) in women
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Vagal-related Heart Rate Variability (HRV) parameters in women
Number of subjects: 74

Group type: COMPARATOR
Intervention: Heart Rate (HR) and Vagal-related HRV parameters in men
Number of subjects: 74
Study: 39301110

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (20 µg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vitamin D insufficiency (<50 nmol/L)
Number of subjects: 0
Study: 39301223

Group type: EXPERIMENTAL
Intervention: Blended Trauma-focused Cognitive Therapy (bTF-CT)
Number of subjects: 17
Study: 39301290

Group type: EXPERIMENTAL
Intervention: Active transcranial alternating current stimulation at alpha frequency
Number of subjects: 22

Group type: COMPARATOR
Intervention: Sham (placebo) transcranial alternating current stimulation
Number of subjects: 22
Study: 39301485

Group type: EXPERIMENTAL
Intervention: 0.01% atropine topical eye drop
Number of subjects: 33
Study: 39301593

Group type: EXPERIMENTAL
Intervention: Stepped care including behavioural and antidepressant therapy (ADT)
Number of subjects: 391

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 391
Study: 39301726

Group type: EXPERIMENTAL
Intervention: Initial invasive management
Number of subjects: 4617

Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 4617
Study: 39301872

Group type: EXPERIMENTAL
Intervention: Early stage borderline ovarian tumor patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Controls (benign ovarian tumors)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups (patients and controls)
Number of subjects: 30
Study: 39301879

Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESAs)
Number of subjects: 5348
Study: 39301983

Group type: EXPERIMENTAL
Intervention: Simulation-based hand hygiene training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Theoretical education and demonstration (Control)
Number of subjects: 60
Study: 39302128

Group type: EXPERIMENTAL
Intervention: Bedsharing
Number of subjects: 457
Study: 39302169

Group type: EXPERIMENTAL
Intervention: DPP Typhoid assay (Chembio) using manufacturer's thresholds
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: DPP Typhoid assay (Chembio) at Youden's optimal threshold
Number of subjects: 385

Group type: COMPARATOR
Intervention: DPP Typhoid assay (Chembio) compared with nine other rapid diagnostic tests
Number of subjects: 385
Study: 39302345

Group type: EXPERIMENTAL
Intervention: Baseline [18F]fluorodeoxyglucose PET/CT imaging
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Molecular subtype
Number of subjects: 185
Study: 39302514

Group type: EXPERIMENTAL
Intervention: Oropharyngeal exercises
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Combined aerobic and oropharyngeal exercises
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 40
Study: 39302529

Group type: EXPERIMENTAL
Intervention: CST IV (non-optimal vaginal microbiota)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: CST I (Lactobacillus crispatus-dominated)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: CST III (Lactobacillus iners-dominated)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Transition from CST III to CST IV
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Transition from CST IV to CST I
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Stable CST trajectory
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Single sample prediction of CST trajectory
Number of subjects: 241
Study: 39302614

Group type: EXPERIMENTAL
Intervention: SG 10 mg/kg
Number of subjects: 51
Study: 39302678

Group type: EXPERIMENTAL
Intervention: Wearable device intervention
Number of subjects: 74

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 74
Study: 39302855

Group type: EXPERIMENTAL
Intervention: Maribavir
Number of subjects: 547

Group type: COMPARATOR
Intervention: Valganciclovir
Number of subjects: 547
Study: 39302924

Group type: EXPERIMENTAL
Intervention: ALVAC+gp120/MF59
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: gp120/MF59 alone
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 39302982

Group type: EXPERIMENTAL
Intervention: CBD-enriched Cannabis Herbal Extract (MPL-001 with a THC:CBD of 1:25), starting at 0.2-0.4 mg/kg of CBD per day and escalating monthly up to 0.8-1.0 mg/kg of CBD per day
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: CBD-enriched Cannabis Herbal Extract (MPL-001 with a THC:CBD of 1:25)
Number of subjects: 20
Study: 39303189

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) with chemotherapy if node-positive
Number of subjects: 68

Group type: COMPARATOR
Intervention: Transoral robotic surgery (TORS) plus neck dissection (± adjuvant RT/chemoradiation)
Number of subjects: 68
Study: 39303200

Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg once every 2 weeks for up to 12 doses)
Number of subjects: 825

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 825
Study: 39303378

Group type: EXPERIMENTAL
Intervention: Virtual Reality Glasses
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Kaleidoscope
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Distraction Cards
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 400
Study: 39303729

Group type: EXPERIMENTAL
Intervention: Decitabine, venetoclax, and ponatinib
Number of subjects: 20
Study: 39303788

Group type: EXPERIMENTAL
Intervention: High-dose quadrivalent influenza vaccine (QIV-HD)
Number of subjects: 12477

Group type: COMPARATOR
Intervention: Standard-dose quadrivalent influenza vaccine (QIV-SD)
Number of subjects: 12477
Study: 39303806

Group type: EXPERIMENTAL
Intervention: Lower Pao2 targets
Number of subjects: 697
Study: 39303988

Group type: EXPERIMENTAL
Intervention: Promoting Resilience in Stress Management (PRISM) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 0
Study: 39304237

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (20 mg/kg to a maximum of 1000 mg)
Number of subjects: 1056

Group type: COMPARATOR
Intervention: Oral ferrous sulphate (200 mg; 65 mg elemental iron) three times daily until 6 weeks postpartum
Number of subjects: 1056

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose
Number of subjects: 1056

Group type: COMPARATOR
Intervention: Oral ferrous sulphate
Number of subjects: 1056
Study: 39304238

Group type: EXPERIMENTAL
Intervention: IPTp with dihydroartemisinin-piperaquine plus targeted information transfer intervention
Number of subjects: 1189

Group type: EXPERIMENTAL
Intervention: IPTp with dihydroartemisinin-piperaquine only
Number of subjects: 1189

Group type: COMPARATOR
Intervention: IPTp with sulfadoxine-pyrimethamine
Number of subjects: 1189
Study: 39304240

Group type: EXPERIMENTAL
Intervention: Mexiletine for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lamotrigine for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison of mexiletine and lamotrigine
Number of subjects: 60
Study: 39304241

Group type: EXPERIMENTAL
Intervention: Subcutaneous efgartigimod PH20 (1000 mg weekly for a maximum of 48 weeks)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Subcutaneous efgartigimod PH20
Number of subjects: 322
Study: 39304362

Group type: EXPERIMENTAL
Intervention: Biomarker levels before PCI
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Biomarker levels 3-days post-initiating PCI
Number of subjects: 48
Study: 39304555

Group type: EXPERIMENTAL
Intervention: Waist-to-height ratio
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Android/gynoid ratio
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Fat mass percentage
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Overweight
Number of subjects: 469
Study: 39304589

Group type: EXPERIMENTAL
Intervention: Text
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Webapp
Number of subjects: 254

Group type: COMPARATOR
Intervention: Text+
Number of subjects: 254

Group type: COMPARATOR
Intervention: Webapp+
Number of subjects: 254

Group type: COMPARATOR
Intervention: Control
Number of subjects: 254